Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease

Abstract INTRODUCTION Donanemab is an immunoglobulin G1 antibody that targets an N‐terminal truncated form of amyloid beta present in mature plaques. Treatment‐emergent (TE) anti‐drug antibodies (ADAs) were quantified in donanemab‐treated participants from two pivotal clinical trials, and effects of...

Full description

Bibliographic Details
Published in:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Main Authors: Garrett R. Mullins, Paul Ardayfio, Ivelina Gueorguieva, Greg Anglin, Jason Bailey, Laiyi Chua, Jennifer A. Zimmer, Cynthia D. Evans, Emel Serap Monkul Nery, Hong Wang, Rashna Khanna, Dawn A. Brooks, John R. Sims
Format: Article
Language:English
Published: Wiley 2025-07-01
Subjects:
Alzheimer's disease
amyloid plaques
anti‐drug antibodies
donanemab
immunogenicity
Online Access:https://doi.org/10.1002/trc2.70149

Internet

https://doi.org/10.1002/trc2.70149

Similar Items